| P50 | author | Kwang-Hyub Han | Q63436668 |
| P2093 | author name string | Seung Up Kim | |
| | Mi Na Kim | |
| | Jun Hyung Kim | |
| P2860 | cites work | Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study | Q24680285 |
| | Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives | Q26822664 |
| | Global cancer statistics, 2002 | Q27860562 |
| | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| | EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 |
| | Histological grading and staging of chronic hepatitis | Q29619625 |
| | Diagnosis, management, and treatment of hepatitis C | Q29620656 |
| | Is liver fibrosis reversible? | Q33862568 |
| | Natural history of hepatitis B virus infection: an update for clinicians | Q34005481 |
| | Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. | Q34264888 |
| | Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression | Q34365464 |
| | Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy | Q34452230 |
| | Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Q34544284 |
| | Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis | Q34571059 |
| | Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. | Q34585594 |
| | Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. | Q46450252 |
| | The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. | Q46713524 |
| | Liver stiffness diminishes with antiviral response in chronic hepatitis C. | Q50555735 |
| | Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. | Q50584684 |
| | Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. | Q51368668 |
| | Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography. | Q51376998 |
| | On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. | Q51584406 |
| | Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. | Q51830742 |
| | Comparison between the M and XL probes for liver fibrosis assessment by transient elastography. | Q53560566 |
| | Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels | Q57205352 |
| | Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B | Q57782726 |
| | Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs | Q58815702 |
| | Changes of non-invasive markers and FibroScan values during HCV treatment | Q34603736 |
| | Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog | Q34632308 |
| | Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study | Q35596325 |
| | Hepatocellular carcinoma: recent trends in the United States | Q35929212 |
| | Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease | Q36014015 |
| | Introduction to chronic hepatitis B infection | Q36382631 |
| | Non-invasive evaluation of liver fibrosis using transient elastography | Q37107626 |
| | Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases | Q37386578 |
| | Current status of liver diseases in Korea: liver cirrhosis | Q37663511 |
| | Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review | Q37997294 |
| | Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir | Q38174251 |
| | Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. | Q39332284 |
| | Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. | Q42210609 |
| | Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. | Q42237621 |
| | Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection. | Q42238105 |
| | Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. | Q42253735 |
| | Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination | Q42285772 |
| | Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir | Q42287100 |
| | Hepatitis B: liver fibrosis and hepatocellular carcinoma | Q42456421 |
| | Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. | Q42871658 |
| | Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. | Q42947269 |
| | Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group | Q42977051 |
| | Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. | Q42984747 |
| | Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study | Q42989003 |
| | Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan | Q42997695 |
| | Peginterferon alfa-2a in patients with chronic hepatitis C. | Q43001243 |
| | Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. | Q43001524 |
| | A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. | Q43033369 |
| | Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease | Q43047208 |
| | Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. | Q43126256 |
| | An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. | Q43285528 |
| | The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin | Q43472585 |
| | Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. | Q43666423 |
| | Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. | Q43875619 |
| | Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. | Q43927506 |
| | Histological outcome during long-term lamivudine therapy. | Q44269261 |
| | Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. | Q44451779 |
| | Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension | Q44506717 |
| | A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis | Q44778119 |
| | Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients | Q45195092 |
| | Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). | Q45369097 |
| | Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis | Q45736423 |
| | Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis | Q45763095 |
| | Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. | Q46249740 |
| P433 | issue | 4 | |
| P921 | main subject | viral hepatitis | Q1983841 |
| P304 | page(s) | 1103-1115 | |
| P577 | publication date | 2014-07-19 | |
| P1433 | published in | Liver International | Q15765078 |
| P1476 | title | Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment | |
| P478 | volume | 35 | |